Schedule III Rescheduling and Cannabinoid Research: What the December 2025 Executive Order Changes for the Regulated Market
On December 18, 2025, the White House issued an Executive Order titled “Increasing Medical Marijuana and Cannabidiol Research.” From an industry perspective, the impact is practical: the order directs federal agencies to accelerate the administrative path toward Schedule III rescheduling, while also prioritizing research methods, product definitions, and guardrails for cannabinoid products.
What the Executive Order Directs
The Executive Order outlines three operational priorities.​
​
1) Accelerate rescheduling rulemaking
It instructs the Attorney General to take the steps needed to complete the rulemaking process to reschedule marijuana to Schedule III as quickly as possible, consistent with federal law.
​
2) Address statutory definitions for certain hemp-derived cannabinoid products
It directs senior White House staff to work with Congress to update the statutory definition of certain hemp-derived cannabinoid products, with the stated goal of preserving access to “appropriate full-spectrum CBD products” while restricting products that pose serious health risks.
​
3) Expand research approaches, including real-world evidence
It calls on federal agencies to develop research methods and models, including real-world evidence, to assess health outcomes and inform standards of care, and references an interest in evaluating longer-term effects in certain populations.
Where the Rescheduling Process Stands
The Executive Order does not itself reschedule cannabis. It directs the government to complete a process that is already underway.
​
The order states that:
-
Marijuana is currently listed under Schedule I of the Controlled Substances Act.
-
In 2023, HHS recommended that marijuana be controlled under Schedule III.
-
In May 2024, DOJ issued a proposed rule to reschedule marijuana to Schedule III, which received nearly 43,000 public comments and is awaiting an administrative law hearing.
​
The most accurate framing for businesses is that the order is a directive to expedite rulemaking, not a statement that rescheduling has already been finalized.
Why Schedule III is a Meaningful Business Threshold
Federal scheduling influences how research is conducted, how medical use is treated in federal definitions, and how regulated markets evolve around reproducible standards.
Under federal statute, Schedule III is associated with a lower abuse potential than Schedules I and II and a “currently accepted medical use” in treatment in the United States (among other criteria).
The Executive Order ties this directly to an industry constraint: limited research capacity and limited clinical guidance on safety, efficacy, and interactions.
The 280E Question: Why Operators Focus on Economics
A key downstream topic around Schedule III is Internal Revenue Code Section 280E.
The statutory text of 26 U.S.C. § 280E disallows deductions or credits for businesses trafficking controlled substances “within the meaning of schedule I and II” of the Controlled Substances Act, when prohibited by federal law or relevant state law.
Because 280E explicitly references Schedules I and II, many operators and analysts focus on whether Schedule III—if finalized—could change the schedule-based tax treatment that has applied to state-legal cannabis businesses. Trade coverage and stakeholder commentary frequently cite this as a material operating economics issue, while still framing it as dependent on the completion of the rescheduling process.
Hemp-derived Cannabinoids: Definitions, Guardrails, and Consistency
The Executive Order also addresses the market reality that hemp-derived cannabinoid products have scaled in an environment with inconsistent standards.
It points toward a regulatory framework that could include guidance on:
An upper limit on milligrams of THC per serving,
Per-container limits, and
CBD:THC ratio requirements.
It also directs HHS, FDA, CMS, and NIH to develop research methods using real-world evidence to inform standards of care and improve access to hemp-derived cannabinoid products in accordance with federal law.
From an industry standpoint, definitional clarity and labeling integrity are not cosmetic. They affect product categorization, compliance posture, and the ability to build programs that can be evaluated consistently.​
Why this Matters for a Technology-driven Ecosystem
For a technology and engineering-led ecosystem, the Executive Order is relevant because it prioritizes conditions the regulated market typically requires to mature: more research capacity, clearer definitions, better guardrails, and more usable evidence.
​
Those factors shape how products are studied, how programs are designed, and how stakeholders evaluate consistency over time—especially in settings where compliance, documentation, and repeatability are baseline expectations.
Source Note
White House Executive Order, Increasing Medical Marijuana and Cannabidiol Research (Dec. 18, 2025).